Skip to content
Research Article Open access CC BY 4.0

Evaluation of Recovery Rate in COVID-19 Patients Treated with Steroidal Drugs

V. V. Rajesham, B. Rekha, Gayathri Kothawar, N. Lavanya, B. Pallavi, T. Rama Rao

Journal of Pharmaceutical Research International · pp. 249–255 · Published 14 Dec 2021

10.9734/jpri/2021/v33i57A33993

Abstract

Introduction: Coronavirus belongs to the family coronaviridae that majorly affects the respiratory system this group of virus outbreak previously as SARS and MERS in various countries and recently as COVID-19. COVID-19 has symptoms like fever, dry cough, breathing problems, loss of smell and taste, body aches. COVID-19 has spread to 210 countries and infected 272.51 million people worldwide, reached over 5.34 million deaths. Treatment includes antivirals, antibiotics, Non Steroidal Anti-Inflammatory Drugs, corticosteroids. Methodology: It is a hospital-based retro-prospective study was conducted for 6 months in the Inpatient department. 100 patients were taken who met the inclusion criteria. Data collected and evaluated, analyzed by open label study. Results and Discussion: severe COVID-19 can develop systemic inflammatory responses that can lead to lung injury and multisystem organ dysfunction. It has been proposed that the potent anti-inflammatory effects of corticosteroids might prevent or mitigate these deleterious effects. Both beneficial and deleterious clinical outcomes have been reported with the use of corticosteroids in patients with other pulmonary infections From study, The Recovery% using steroids in the time period of 0-10 and 11-20 days was found to be 34 and 27% respectively. The Recovery percentage using steroids in the time period of 0-10 and 11-20 days was found to be 18 and 8% respectively. Dexamethasone was most commonly used in males and females, 77.08 and 84% respectively. Conclusion: Considering beneficial effects of corticosteroids in COVID -19, prescribing steroids is safe by dose tapering continued up to 10days or hospital discharge

COVID-19 Corticosteroids Dexamethasone Prednisolone

References (13)

  1. 1 A Novel Coronavirus Associated with Severe Acute Respiratory Syndrome [DOI]
  2. 2 Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury [DOI]
  3. 3 SARS: Systematic Review of Treatment Effects [DOI]
  4. 4 Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome [DOI]
  5. 5 The epidemiology, diagnosis and treatment of COVID-19 [DOI]
  6. 6 Corticosteroids in the Treatment of Severe Sepsis and Septic Shock in Adults [DOI]
  7. 7 Corticosteroids as adjunctive therapy in the treatment of influenza [DOI]
  8. 8 Corticosteroids for treating sepsis in children and adults [DOI]
  9. 9 Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019 [DOI]
  10. 10 COVID-19: The outbreak caused by a new coronavirus [DOI]
  11. 11 Corticosteroids for Treating Sepsis in Children and Adults [DOI]
  12. 12 Corticosteroids and Infectious Diseases [DOI]
  13. 13 Corticosteroids as adjunctive therapy in the treatment of influenza [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

1

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.